Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaFaith E. Davies, Kenneth C. Anderson, Noopur Raje et al.|Blood|2001Cited by 905
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengaß, Suzanne Lentzsch, Sagar Lonial et al.|The Lancet Oncology|2019Cited by 493
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working GroupPhilippe Moreau, Jean‐Luc Harousseau, Shaji Kumar et al.|The Lancet Oncology|2021Cited by 266
Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic diseaseJing Fu, Suzanne Lentzsch|Journal of Clinical Investigation|2016Cited by 73
Targeting the Microtubular Network as a New Antimyeloma StrategyRentian Feng, Suzanne Lentzsch|Molecular Cancer Therapeutics|2011Cited by 28